Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer - PubMed
3 days ago
- #ctDNA
- #utDNA
- #bladder cancer
- Clinical trial tests bladder-sparing approach for muscle-invasive bladder cancer (MIBC) patients with complete response post-therapy.
- 3-year bladder-intact survival rate is 69% for patients with complete clinical response after systemic therapy.
- Detectable ctDNA before systemic therapy correlates with higher metastatic risk (HR 4.68).
- Only 4.5% of patients with undetectable baseline ctDNA developed metastatic disease.
- Urine utDNA is more sensitive than plasma ctDNA in detecting residual bladder disease.
- Detectable utDNA in complete responders linked to shorter bladder-intact survival (HR 6.47).
- Findings support integrating ctDNA and utDNA assays in MIBC management to guide cystectomy decisions.